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Abstract
Background: Rasd1 is a member of the Ras family of monomeric G proteins that was first identified as a
dexamethasone inducible gene in the pituitary corticotroph cell line AtT20. Using microarrays we previously
identified increased Rasd1 mRNA expression in the rat supraoptic nucleus (SON) and paraventricular nucleus (PVN)
of the hypothalamus in response to increased plasma osmolality provoked by fluid deprivation and salt loading.
RASD1 has been shown to inhibit adenylyl cyclase activity in vitro resulting in the inhibition of the cAMP-PKA-CREB
signaling pathway. Therefore, we tested the hypothesis that RASD1 may inhibit cAMP stimulated gene expression
in the brain.
Results: We show that Rasd1 is expressed in vasopressin neurons of the PVN and SON, within which mRNA levels
are induced by hyperosmotic cues. Dexamethasone treatment of AtT20 cells decreased forskolin stimulation of
c-Fos, Nr4a1 and phosphorylated CREB expression, effects that were mimicked by overexpression of Rasd1, and
inhibited by knockdown of Rasd1. These effects were dependent upon isoprenylation, as both farnesyltransferase
inhibitor FTI-277 and CAAX box deletion prevented Rasd1 inhibition of cAMP-induced gene expression. Injection of
lentiviral vector into rat SON expressing Rasd1 diminished, whereas CAAX mutant increased, cAMP inducible genes
in response to osmotic stress.
Conclusions: We have identified two mechanisms of Rasd1 induction in the hypothalamus, one by elevated
glucocorticoids in response to stress, and one in response to increased plasma osmolality resulting from osmotic
stress. We propose that the abundance of RASD1 in vasopressin expressing neurons, based on its inhibitory actions
on CREB phosphorylation, is an important mechanism for controlling the transcriptional responses to stressors in both
the PVN and SON. These effects likely occur through modulation of cAMP-PKA-CREB signaling pathway in the brain.
Background
The hypothalamo-neurohypophyseal system (HNS) is
the source of the neuropeptide hormone arginine vaso-
pressin (AVP). AVP is synthesised in magnocellular neu-
rons (MCN) of the supraoptic nucleus (SON) and
paraventricular nucleus (PVN) and is transported ante-
rogradely to terminals in the posterior pituitary gland. A
rise in plasma osmolality increases secretion of AVP into
the blood stream where it promotes water reabsorption
at the kidney [1].
While the SON contains a homogenous population of
MCN, the PVN is divided into MCN and parvocelluar
neurons (PCNs). The PCNs form part of the
hypothalamo-pituitary-adrenal (HPA) axis that mediates
the stress response. In response to restraint stress, AVP
and corticotropin releasing hormone (CRH) are released
from the PCN axon terminals in the median eminence
into the portal vasculature [2–4] that supplies the anterior
pituitary to stimulate the release of adrenocorticotropin
hormone [5, 6], and, subsequently, glucocorticoids from
the adrenal cortex. These secretory responses are accom-
panied by transcriptional increases in Avp and Crh in
PCN by stress [7–9] and Avp in MCN of the hypothal-
amus by osmotic stress [10].
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The signaling mechanisms governing transcriptional
increases in Crh and Avp are believed to involve cAMP
activation of the protein kinase A (PKA) pathway and
the subsequent phosphorylation of cAMP response
element binding protein (CREB) [11]. It is known
that both hyperosmotic and restraint stress increase
the abundance of phosphorylated CREB, a process
that occurs within minutes of stimulation in MCN
and PCNs [8, 9, 12, 13]. Stress induced transcrip-
tional increases can be short-lived, particularly for
Crh and Avp in PCNs, as the subsequent increase in
circulating levels of glucocorticoid following stress,
through its interactions with glucocorticoid receptors
(GR) within these neurons [14], rapidly dampens this
transcriptional response. This feedback by glucocorti-
coids has been reported to inhibit CREB phosphoryl-
ation in PCNs [12], through a proposed unknown
intermediate intracellular signaling molecule regulat-
ing cAMP [7]. Less is known about inhibitory inputs
controlling the transcriptional response to osmotic
stress in MCN of the PVN and SON where phos-
phorylated CREB levels also increase [13]. MCN of
the SON express GRs [15], and expression has been
shown to increase during hypoosmotic stress [16], in-
dicating that glucocorticoid negative feedback is a
possible route for regulation, though studies suggest
considerably lower levels of this receptor compared
to PCNs of the PVN [14, 17]. Nonetheless, we rea-
soned that a glucocorticoid inducible gene might be
important for regulating transcriptional feedback in-
hibition in both MCN and PCNs.
Our candidate was Rasd1 (dexamethasone inducible
Ras protein 1, Dexras1), a member of the Ras family of
monomeric G proteins that was first identified as a
dexamethasone (DEX) inducible gene in the pituitary
corticotroph cell line AtT20 [18]. A putative glucocortic-
oid response element identified by Kemppainen and col-
leagues [19] in the 3’ flanking region of the human
Rasd1 gene was shown to confer rapid responsiveness to
glucocorticoids by reporter assay. Indeed, the peripheral
administration of DEX in rats and mice strongly and
rapidly induces Rasd1 expression in several tissue types,
including the brain [18, 20, 21]. Another important fea-
ture of Rasd1 is its role as an inhibitor of adenylyl cy-
clase (AC) activity [22–25]. An in vitro study by Graham
et al. [22] showed that Rasd1 inhibits GαS- and forskolin
(FSK)-induced increases in cAMP levels through ligand
independent activation of the Gαi and Gβγ arms of the
Gi signaling pathway. This results in inhibition of the
cAMP-PKA-CREB signaling pathway and so forms a
possible feedback mechanism for regulation of MCN
and PCNs. There is also in vitro evidence from reporter
assays that Rasd1 acts at cAMP response element (CRE)
sites within target gene promoters, to directly inhibit
transcription [26, 27]. Thus, Rasd1 has the capacity to
influence transcriptional events either indirectly, by inhi-
biting AC activity at the cell membrane, or directly,
through modulation of activity at the level of the
promoter.
Using microarrays we identified increased Rasd1 ex-
pression in the rat and mouse SON in response to
hyperosmotic stress (dehydration) [28, 29]. Rasd1
mRNA expression has previously been described in
the mouse PVN and SON but its function in these
brain nuclei is not known [30, 31]. Only in the supra-
chiasmatic nucleus (SCN) of the brain has Rasd1 ex-
pression been interrogated thoroughly [32]. Rasd1
cycles with a circadian rhythm that oscillates in anti-
phase with many of the cAMP inducible mRNAs in
the SCN [31] including Avp. Interestingly, in the
SCNs of Rasd1 knockout mice, Cheng et al. [26] re-
ported higher cAMP levels alongside increased CREB
phosphorylation compared to wild-type mice. We thus
hypothesised that Rasd1 may control the transcription
of cAMP inducible genes, and ultimately their down-
stream targets, Avp and Crh, in the hypothalamus.
Using in vitro and in vivo approaches we demonstrate
that Rasd1 negatively regulates the hypothalamic tran-
scriptional response to stimulation by hyperosmotic
stress in the rat.
Results
Rasd1 mRNA expression in the rat hypothalamus in
response to different stressors
We first investigated the time course of Rasd1 mRNA
expression in the PVN and SON of control, dehydrated
(DH) and salt loaded (SL) rats using qPCR (Fig. 1a).
Rasd1 mRNA expression was significantly higher in the
PVN and SON of 1 day (day) DH and 1 day SL rats
compared with control rats. Increasing the duration of
hypertonic stress to 3 days DH and 7 days SL further in-
creased the magnitude of this response in both PVN and
the SON. When drinking water was returned after 1 day
DH and 1 day SL, Rasd1 mRNA abundance was seen to
quickly return to control levels (Fig. 1b).
We then examined the acute response of Rasd1 tran-
scripts to a single intraperitoneal (i.p) injection of hyper-
tonic saline (HS) (Fig. 1c). The abundance of the Rasd1
mRNA increased rapidly after injection in both PVN
and SON, and levels progressively increased until peak-
ing at around 60 min, with levels remaining steadily ele-
vated thereafter. As Rasd1 is known to be strongly
induced by glucocorticoids [18], we also examined ex-
pression in PVN and SON resulting from stress induced
by 30 min and 1 h restraint (Fig. 1d). An increase of
Rasd1 mRNA was observed in PVN but interestingly
not the SON.
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Expression of RASD1 protein in the rat HNS
Immunofluorescent localisation studies were performed
to determine the cell populations expressing RASD1 in
the PVN and SON of control rats (Fig. 2). RASD1 was
expressed MCN of the PVN and SON (Fig. 2a). In the
PVN, RASD1 staining was predominantly found in the
lateral magnocellular part with fewer RASD1 positive
neurones in parvocellular regions. The MCN of the
SON and PVN can be divided into two populations, ex-
pressing either AVP, or the closely related neuropeptide
hormone oxytocin (OT), with only a small percentage
(2–3%) of MCN express high, equivalent levels of both
peptides [33]. Therefore, to examine the identity of neu-
rons expressing RASD1 in the PVN and SON, co-
immunostaining of RASD1 with AVP neurophysin-II or
OT neurophysin-I was performed in euhydrated control
rats (Fig. 2b–c). RASD1 expression was observed in AVP
positive (Fig. 2b), but not OT expressing MCN of the
PVN and SON (Fig. 2c). High magnification images
using confocal microscopy are shown in Fig. 2d.
Therefore, one can assign the potential functions of
Rasd1 principally to vasopressinergic neurones in
these two brain nuclei following hyperosmotic stress.
The specificity of the RASD1 antibody was confirmed
Fig. 1 Rasd1 mRNA expression in the rat PVN and SON in response of hyperosmotic stress (a–c). The expression of Rasd1 was examined in the
PVN and SON in chronic and acute hyperosmotic conditions, and following water repletion. Relative mRNA expression of Rasd1 was investigated
by qPCR in the PVN and SON of a control, DH (1 and 3 days), and SL (1 and 7 days) rats, b after water repletion for 1 day after 1 day DH and
1 day SL compared to controls, c after a single i.p injection of 1.5 ml/100 g body weight 1.5 M NaCl over a 4 h experimental period compared to
controls. d, Rasd1 mRNA expression in PVN and SON after 30 min and 1 h restraint stress compared to control. All data was analysed by One-way
ANOVA. Values are means + SEM of n = 5−6 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001. RH, rehydration; Con, control
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in N2a cells transfected with GFP-Rasd1 fusion con-
struct (Fig. 2e).
Effect of osmotic and restraint stress on RASD1 protein
distribution
Immunofluorescence staining was performed to examine
the expression of RASD1 after exposure to either os-
motic or restraint stress (Fig. 3). The intensity of RASD1
staining in neuronal cell bodies of the PVN and SON
appeared similar in DH but lower in SL compared to
control rats (Fig. 3a). We then looked at the distribution
of RASD1 staining in the PVN after restraint stress
(Fig. 3b). The degree of RASD1 staining appeared higher
in the dorsomedial parvocellular portions in response to
restraint stress (Fig. 3b).
Activation of Rasd1 transcription by glucocorticoids in the
PVN and SON
Peripheral treatment with DEX has been reported to
rapidly and robustly increase the expression of Rasd1
mRNA in the brain [21]. To determine if Rasd1
expression was stimulated by glucocorticoids specifically
in PVN and SON, we performed ex vivo and in vivo ex-
periments with DEX (Fig. 4). Incubation of hypothalamic
organotypic cultures for 4 h and 24 h in the presence of
DEX significantly increased Rasd1 mRNA expression in
both the PVN and SON compared to controls (Fig. 4a).
Next, to investigate glucocorticoid actions on Rasd1 ex-
pression in vivo, rats were injected with DEX before in-
jection of isotonic (IS) or HS. At 30 min after saline
injection mRNA levels were examined in the PVN and
SON (Fig. 4b). As expected, HS injection significantly in-
creased Rasd1 mRNA expression in PVN and SON
compared to the vehicle control. DEX injection in-
creased Rasd1 mRNA expression in PVNs and SONs of
rats administered IS, in agreement with our findings for
organotypic cultures. However, there was no significant
difference in Rasd1 mRNA in PVNs of rats treated with
DEX and IS compared to vehicle and HS, whilst in the
SON, HS treatment significantly increased Rasd1 ex-
pression compared to rats treated with DEX and IS.
Moreover, DEX injection increased hypertonic induced
Fig. 2 Immunofluorescent localisation of RASD1 in the hypothalamus of the euhydrated rat. a, immunofluorescent localisation of RASD1 in MCN
of the PVN and SON. b–c immunofluorescent colocalisation of RASD1 (green) with b AVP (red) and c OT (red) in MCN in the PVN and SON. d
Higher magnification images showed the presence of Rasd1 in AVP, but not OT, positive cells. e, eGFP and Rasd1 fluorescence in N2a cells
transfected with eGFP-Rasd1 fusion construct. Dapi staining indicates the nucleus. Scale bars a–c = 100 μm, d–e = 10 μm. OC, optic chiasm; 3 V,
third ventricle
Greenwood et al. Molecular Brain  (2016) 9:1 Page 4 of 17
Rasd1 mRNA expression in both PVN and SON com-
pared to vehicle controls, perhaps suggesting activation
of Rasd1 expression by separate molecular pathways.
We next focused our attention on the expression of
the Avp and Crh mRNAs, their respective precursor
transcripts, heteronuclear Avp (hnAvp) and heteronuc-
lear Crh (hnCrh), the assessment of which acts as a sur-
rogate measure for transcription [34, 35]. We also
looked at two established cAMP inducible transcription
factors, c-Fos and nuclear receptor subfamily 4 group A
member 1 (Nr4a1), the expression of which are known
to be induced both by CREB phosphorylation and os-
motic stress (reviewed by Yoshida, 2008 [11]). DEX in-
jection reduced HS induced hnAvp, hnCrh, c-Fos and
Nr4a1 expression in the PVN and c-Fos and Nr4a1 in
the SON. Basal levels of gene expression of these genes
were unchanged by DEX treatment, with the exception
hnCrh expression which was lower in the PVN. We then
asked if treatment with metyrapone (MET), which
blocks corticosterone synthesis [36], could influence
basal Rasd1 mRNA expression, or its response to HS in
the PVN and SON (Fig. 4c). Basal Rasd1 mRNA expres-
sion was unchanged by MET treatment in the PVN and
SON. However, hypertonic induced Rasd1 mRNA ex-
pression was diminished by pretreatment with MET,
though still elevated above control measures, in the
PVN and this effect was recovered by combined treat-
ment with DEX. Rasd1 mRNA expression was un-
changed by any of these treatments in the SON.
DEX and Rasd1 inhibit cAMP induced gene expression in
AtT20 cells
The stimulatory actions of glucocorticoids on Rasd1
gene expression were first described in AtT20 cells [18].
We initially treated AtT20 cells with DEX concentra-
tions ranging from 0.01–1000nM to establish a suitable
concentration for our studies (Fig. 5a). Maximum stimu-
lation of Rasd1 mRNA expression was observed at
100nM so we selected this dose for our in vitro studies.
Treatment with DEX increased Rasd1 in a time
dependent manner (Fig. 5b), with significance reached at
30 min, and maximum expression between 1–2 h,
Fig. 3 The effect of osmotic and restraint stress on RASD1 expression. a, immunofluorescent staining for RASD1 in the PVN and SON of control,
3 days DH and 7 days SL rat. High magnification confocal images are shown. b, immunofluorescent staining of RASD1 in the rat PVN in response
1 h restraint stress with 3 h recovery. Arrows indicate the dorsomedial parvocellular portion of PVN. Scale bars a–b = 100 μm, confocal images =
10 μm. OC, optic chiasm; 3 V, third ventricle; Con, control
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similar to the effect of acute hypertonic stimulation in
vivo (Fig. 1c). We produced shRNAs to knockdown
Rasd1 expression. Of the two Rasd1 shRNAs we tested,
shRNA2 showed significant knockdown of Rasd1 mRNA
(Fig. 5c). We then examined the effect of DEX treatment
on Rasd1 mRNA expression in the Rasd1 knockdown
cell line. The result showed that, from its significantly
diminished baseline, Rasd1 mRNA increased in abun-
dance, suggesting that the knockdown cell line is still
able to respond to DEX, but the level of Rasd1 mRNA
expression was significantly reduced compared to the
control shRNA cells.
We next asked if the DEX inhibition of c-Fos and
Nr4a1 mRNAs seen in vivo was the result of increased
Rasd1 expression. We used FSK to induce endogenous
c-Fos and Nr4a1 expression over a time course of 4 h in
AtT20 cells pretreated with DEX. As seen in our in vivo
study, DEX treatment significantly inhibited c-Fos and
Nr4a1 expression in AtT20 cells (Fig. 5d). To establish if
Rasd1 could be mediating these DEX effects, we firstly
Fig. 4 DEX induced Rasd1 mRNA expression in the rat PVN and SON. a the addition of DEX to hypothalamic organotypic culture media 4 or 24 h
before collection of samples increased the expression of Rasd1 in the PVN and SON compared to vehicle (DMSO) controls. b rats were injected with
DEX (1 mg/kg) or vehicle (0.15 M NaCl) 2 h before i.p injection of IS (0.15 M NaCl) or HS (1.5 M NaCl; 1.5 ml/100 g body weight). Brains were collected
30 min after IS or HS injection. qPCR was performed to analyse the expression of Rasd1 c-Fos, Nr4a1, hnAvp and hnCrh in PVN and SON. c to block
endogenous glucocorticoid synthesis rats were injected with MET or a combination of MET and DEX 4 h before i.p injection of IS or HS. Brains were
collected after 30 min and qPCR analysis was performed on the cDNAs generated. a, independent-sample unpaired Student’s t tests; b–c, Two-way
ANOVA. Values are means + SEM of n = 5−8 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001. DEX, dexamethasone; MET, Metyrapone; VEH, vehicle
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overexpressed Rasd1 or eGFP in AtT20 cells using
adenoviral vectors, and then treated the transfected cells
with FSK to stimulate endogenous c-Fos and Nr4a1 ex-
pression. Increasing Rasd1 expression inhibited FSK
stimulation of c-Fos and Nr4a1 with a remarkably
similar time course and level of inhibition to that of
DEX treatment. shRNA mediated knockdown of en-
dogenous Rasd1 increased FSK-stimulated Nr4a1 ex-
pression, but not c-Fos expression compared to the
control shRNA. DEX inhibited FSK-stimulated Nr4a1
Fig. 5 Rasd1 mediates actions of glucocorticoid on transcription factors c-Fos and Nr4a1 in AtT20 cells. a, Rasd1 mRNA expression in response to
1 h treatment with different concentrations of DEX. b changes in Rasd1 mRNA expression after treatment with 100nM DEX over a 4 h
experimental period compared to time matched vehicle controls. c responses to Rasd1 knock down cell lines to 1 h treatment with 100nM DEX
were examined by qPCR compared to a control non-targeting shRNA cell line. d the effect of pretreatment with DEX (2 h), 72 h of adenoviral
mediated Rasd1 overexpression and Rasd1 knockdown on FSK (10 μM) induced c-Fos and Nr4a1 mRNA expression was examined compared to
controls. e cells were infected with Rasd1 adenovirus for 4 h. Media was replaced and cells were grown in the presence of farensyltransferase
inhibitor FTI-277 for 72 h and qPCR analysis of c-Fos and Nr4a1 expression was performed. f the effect of 72 h of adenoviral mediated dnRasd1
overexpression on FSK induced c-Fos and Nr4a1 mRNA expression was examined compared to controls. g responses of GR knockdown cell lines
to treatment with 100nM DEX were examined by qPCR compared to a control non-targeting shRNA cell line. VEH, vehicle; NT, non-targeting;
Con, control. Values are means + SEM of n = 3−4 per group. *p < 0.05, **p < 0.01, ***p < 0.001
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but not c-Fos in both Rasd1 and non-targeting shRNA
cell lines, but expression of Nr4a1 remained higher than
the control cell line. This may be expected as DEX was
still able to increase Rasd1 mRNA in the knockdown cell
line (Fig. 5c). When we treated Rasd1 overexpressing
cells with the farnesyltransferase inhibitor FTI-277, a
highly potent CAAX peptidomimetic that inhibits Ras
signaling [37], FSK-stimulated expression of c-Fos and
Nr4a1 increased compared to control (Fig. 5e). Adeno-
viral mediated overexpression of a CAAX box deficient
Rasd1 (dnRasd1) significantly increased c-Fos and Nr4a1
expression confirming the importance of this motif
(Fig. 5f ).
The GR is believed to be responsible for mediating the
effects of DEX on Rasd1 mRNA expression. Therefore,
we produced a GR knockdown AtT20 cell line and
tested the responsiveness of Rasd1 expression to treat-
ment with DEX (Fig. 5g). shRNA mediated silencing of
GR expression abolished Rasd1 stimulation by DEX,
confirming that Rasd1 activation is mediated by GR
dependent signaling pathways in AtT20 cells. We specu-
lated that Rasd1 provoked these changes in gene expres-
sion may result from altered CREB phosphorylation,
which is a known regulator of c-Fos and Nr4a1 (Fig. 6).
Indeed CREB phosphorylation was reduced by both
DEX (Fig. 6a) and Rasd1 (Fig. 6b), but was increased by
overexpression of dnRasd1 (Fig. 6c).
Rasd1 expression controls the transcriptional response to
hyperosmotic stress in vivo
We asked about the transcriptional effects of Rasd1
overexpression in the SON in vivo. We confirmed ex-
pression of the Rasd1 and dnRasd1 lentiviruses in N2a
cells by immunoblot (Fig. 7a) and in MCN of the SON
using the eGFP tag (Fig. 7b). Quantitative PCR con-
firmed the overexpression of Rasd1 in the SON (Fig. 7c).
We then examined gene expression in SON injected
with Rasd1 compared to eGFP controls. Basal levels of
c-Fos, Nr4a1 and hnAvp were unaffected by overexpres-
sion of Rasd1 compared to eGFP controls. The expres-
sion of all of these genes was increased by HS injection
in eGFP virus injected SONs. In Rasd1 injected SON,
HS induced smaller rises in c-Fos and Nr4a1 expression
compared to controls and inhibited HS induced hnAvp
expression. We then directly assessed the importance of
Rasd1 in the hypothalamic systems controlling homeo-
stasis using the SL model in rats injected with dnRasd1
virus (Fig. 7d). Quantitative PCR confirmed higher ex-
pression of Rasd1 in SON injected with dnRasd1 com-
pared to eGFP controls. The expression of dnRasd1 in
the SON increased expression of c-Fos, Nr4a1 and
hnAvp in SL rats compared to eGFP controls. However,
the increase of c-Fos expression did not reach statistical
significance.
Discussion
Rasd1 is becoming somewhat of avant-garde member of
the Ras family of GTPases by performing many non-
conventional signaling functions. Our identification of
Rasd1 in Avp neurons starts a new chapter for this small
GTPase. Here we show that Rasd1 is rapidly induced by
stress in the PVN, and by elevated plasma osmolality in
the PVN and SON of the hypothalamus. We propose
that the abundance of RASD1 in MCN and PCNs, based
on its inhibitory actions on CREB phosphorylation, is an
important mechanism for controlling the transcriptional
Fig. 6 Rasd1 reduces the abundance of phosphorylated CREB in FSK stimulated AtT20 cells. Phosphorylated CREB expression in AtT20 cells (a)
treated with FSK (5, 10, 20, 60 min) after 2 h pretreatment with DEX, b 72 h adenoviral overexpression of Rasd1 or c 72 h adenoviral expression of
dnRasd1 by Western blot. Viral overexpression of Rasd1 was confirmed. GAPDH was used as the loading control. Con, control; VEH vehicle
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responses to stressors in both the PVN and SON. In
MCN we show, by virally mediated overexpression of
Rasd1, that Rasd1 inhibits HS induced stimulation of
cAMP inducible genes. When a CAAX box deficient
mutant form of Rasd1 is expressed in the SON cAMP
inducible genes were further increased by SL. These ef-
fects likely occur through modulation of cAMP-PKA-
CREB signaling pathway.
Our interest in Rasd1 began following identification
increased expression of this gene in the SON of the
3 days DH rat using microarrays [28]. Here, using
qPCR, we confirmed increased Rasd1 expression in
rat PVN and SON by DH, SL and HS injection.
These protocols have all been shown to increase
plasma corticosterone levels in the rat [38–41], sug-
gesting that glucocorticoids may be responsible for in-
creased Rasd1 mRNA expression in the brain. To test
this notion, we performed restraint stress, where
plasma corticosterone levels are increased [42, 43] in
the absence of the osmotic cues presented by hyper-
osmotic stress. To our surprise, restraint stress rapidly
increased Rasd1 expression, but only in the PVN,
suggesting differing mechanisms of Rasd1 activation
in the PVN and SON by restraint stress and osmotic
stress. We show here in AtT20 cells that the GR is
important for Rasd1 induction by DEX similar to pre-
vious reports for other cell lines [44]. We thus pro-
posed that the location of GRs in the hypothalamus
likely underlies these differing responses to restraint
stress. Indeed, in support of this concept, PCNs of
the PVN are known to express comparatively higher
levels of the GR than MCN of the SON [14–17].
These data thus imply different mechanisms of Rasd1
activation in PCNs and MCN.
Fig. 7 Lentiviral mediated manipulation of Rasd1 expression in the rat SON alters c-Fos, Nr4a1 and hnAvp expression. a confirmation of Rasd1
protein expression 72 h after viral transduction in mouse neuronal cell line N2a. b lentiviral transduction of MCN in the SON 2 weeks after
injection. c rats were injected into SON with lentiviral vectors expressing Rasd1 or eGFP. Two weeks after viral administration rats received a single
i.p injection of either IS (0.15 M NaCl) or HS (1.5 M NaCl; 1.5 ml/100 g body weight). Brains were collected 30 min later. Relative expression of
c-Fos, Nr4a1, hnAvp and Rasd1 was determined by qPCR. d two weeks after dnRasd1 injection rats were presented with 2% (w/v) NaCl solution in
place of drinking water for 7 days. Relative expression of c-Fos, Nr4a1, hnAvp and Rasd1 in SON of dnRasd1 delivered animals compared to control
eGFP control. c, Two-way ANOVA; d, independent-sample unpaired Student’s t tests. Scale bars = 100 μm. Con, control; MOI, multiplicity of
infection. Values are means + SEM of n = 4−5 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001
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The observed expression of Rasd1 exclusively in AVP
positive neurons suggested a role in the regulation of
these neurons. Such regulation may occur at multiple
levels: as we observed Rasd1 expression in neuronal cell
body, dendrites and axons of control rats. The presence
of Rasd1 in axons is novel, but this property is not
unique to this particular Ras protein. In the mouse
hippocampus another member of the Ras family, H-Ras,
a potent activator of ERK signaling, has previously been
identified in axon terminals [45]. Transgenic mice over-
expressing a constitutively active mutant of H-Ras,
which strongly localises to axon terminals in the hippo-
campus, resulted in several presynaptic changes includ-
ing a higher density of docked neurotransmitter vesicles
in glutamatergic terminals [45]. The granular cytoplas-
mic pattern of RASD1 immunoreactivity in the neuronal
cell body suggests that RASD1 may be associated with
vesicular structures in the cytoplasm. The presence of
RASD1 in cell processes suggests that RASD1 has
secretory role in AVP neurons. The idea that Rasd1
could influence hormone secretion is not new. A num-
ber of in vitro studies have reported inhibitory actions of
Rasd1 on hormone secretion but the precise mecha-
nisms mediating these inhibitory effects remains to be
established [21, 46–48]. It is established that high plasma
osmolality results in the secretion and depletion of AVP
in MCN cell bodies, even though mRNA expression of
Avp is up-regulated in the PVN and SON [49, 50]. This
is also true for RASD1 in SL rats. What is known is that
RASD1 regulates a number of cell signaling processes
[51, 52], in particular it has inhibitory actions on the
cAMP-PKA-CREB signaling pathway [21–25]. There-
fore, any changes in cellular abundance of RASD1, as
we observe here in the MCN cell bodies by hyperos-
motic stress and the increase in PCN by restraint
stress, would be expected to influence the cAMP sig-
nalling pathway.
The expression of Rasd1 in the brain has been shown
to be under hormonal control [20]. We show here that
DEX increases Rasd1 expression in the PVN and SON
of the hypothalamus. These findings differed from our
observations in restraint stress where Rasd1 increased
only in the PVN. One possibility for these differences is
the greater potency of DEX in its glucocorticoid effects
than endogenous corticosterone. Our data showed that
pretreatment with DEX potentiated HS induced in-
creases in Rasd1 expression in PVN and SON, consist-
ent with our hypothesis of two separate mechanisms
activating Rasd1 transcription in these nuclei. This was
confirmed by treatment with MET, which decreased
Rasd1 expression only in the PVN, a response that was
effectively rescued by DEX. These findings are consistent
with the presence of GRs in MCN of the SON a well as
PCN of the PVN [15, 16]. These data thus imply two
separate mechanisms of Rasd1 activation in the PVN
and SON, one sensitive to glucocorticoids, and one me-
diated by a currently undefined mechanism in response
to elevated plasma osmolality.
The negative feedback of glucocorticoids, in our case
using DEX, on hnAvp and hnCrh transcription in PVN
has been known for many years [7, 53–55]. Withdrawal
of glucocorticoids by adrenalectomy results in increased
Crh and Avp mRNA expression in the PVN [56, 57],
which can be reversed by glucocorticoid replacement
[7]. In adrenalectomised rats, by replacing cortico-
sterone, Kovacs et al. demonstrated that glucocorticoids
selectively targets Avp transcription in PCNs and not
MCN of the PVN [7]. In PCNs of the rat PVN, these
transcriptional events are thought to be mediated by
stress induced increases in CREB phosphorylation,
which results in increased Crh and Avp transcription [8,
9, 12]. Inhibition CREB phosphorylation is thought to be
one of the targets for the negative feedback of glucocor-
ticoids on Avp and Crh transcription in PCN of the PVN
[7, 12]. Furthermore, it is known that cAMP increases in
the SON in response to hyperosmotic stress [58–60],
through activation of the PKA pathway and subsequent
CREB phosphorylation [13], and this is thought to
stimulate Avp transcription.
In recent years many in vivo actions of DEX have been
attributed to molecular signaling through Rasd1 [44, 46,
47] suggesting that DEX actions in the hypothalamus
were the result of increased Rasd1 expression. Our in
vivo observations of altered c-Fos and Nr4a1 expression
by DEX treatment in the PVN and SON, where Rasd1
expression is elevated, prompted us to compare DEX
treatment with Rasd1 overexpression on gene expression
in mouse corticotroph AtT20 cells. Both c-Fos and
Nr4a1 are well established cAMP inducible genes that
are induced by phosphorylated CREB [61], and respond
robustly to increases in neuronal activity arising from
osmotic stress and restraint stress [62, 63]. There is also
evidence that DEX inhibits c-Fos and Nr4a1 expression
[53, 55, 64], so we speculated that these effects could be
mediated by Rasd1 via modulation of cAMP-PKA-CREB
signaling pathway. We show by overexpression and
knockdown, that Rasd1 can reproduce DEX effects on c-
Fos and Nr4a1 in AtT20 cells, suggesting that glucocor-
ticoids primarily act through Rasd1 to inhibit the ex-
pression of these transcription factors.
RASD1 has also been shown to inhibit cAMP indu-
cible genes through interactions at the promoter.
RASD1 interacts with NonO, a member of RNA-
Recognition motif gene family, at cAMP response elem-
ent (CRE) sites within target genes, including Nr4a1,
inhibiting their transcription [27]. Furthermore, in cor-
tical neuron cultures, transfection of a CRE driven lucif-
erase construct also demonstrated the inhibitory actions
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of RASD1 on FSK induced CRE mediated transcription
[26]. The transcriptional changes in the present study
were isoprenylation dependent as determined using the
farnesyltransferase inhibitor FTI-277 and the CAAX de-
ficient dnRasd1 suggesting membrane translocation is
necessary. RASD1 undergoes posttranslational modifica-
tions by farnesylation of its CAAX box [25] similar to
other members of the Ras family [65]. Isoprenylation of
this CAAX consensus site is required for translocation
of Ras proteins to the cell membrane [65, 66], stimula-
tion of protein-protein interactions, and can affect pro-
tein stability [67]. Isoprenylation has been shown to
reduce the stability of Ras proteins [68] and is thought
to be necessary for rapid protein turnover of GTPase
RhoB [69]. The decreased stability of farnesylated pro-
teins may provide an explanation for the lower levels
RASD1 observed in the PVN and SON during SL, which
may be the result of increased turnover of RASD1 pro-
tein. These data imply that the observed actions of
Rasd1 in AtT20 cells occur through regulation of G pro-
teins at the plasma membrane.
The expression of over 100 non-chemosensory G pro-
tein coupled receptors has been described in the PVN
and SON [70], many of which could be subject to regu-
lation by RASD1. Indeed, it has been proposed that
RASD1 may act to antagonise G protein coupled recep-
tor signaling by altering the pool of heterotrimeric G-
proteins available for receptor coupling [71]. Interest-
ingly, Rasd1 has been reported to selectively activate
transient receptor potential channel 4 (TRPC4) in INS-I
cells [72], and altered expression of these channels has
been described in vasopressinergic MCNs of the PVN
and SON in response to hyperosmotic stress [28, 73].
The activation of TRPC4 in neurosecretory cells is
known to trigger a robust secretory response [74], sug-
gesting that Rasd1 may affect the secretion of vasopres-
sin. Furthermore, Rasd1 has been shown to modulate N-
type calcium channels in HEK293 cells [75]. Thus,
Rasd1 has the capacity to modulate calcium influx into
cells and may influence calcium dependent events such
as vasopressin secretion from MCNs. Therefore, in
hypertonic stress altered RASD1 expression may perhaps
modulate the excitability of MCNs by altering channel
activity, though this remains to be determined.
Rasd1 overexpression has been shown to inhibit GαS
and FSK mediated activation of AC through activation
of Gαi and Gβγ [22]. Interestingly, SL in rats increases
Gαi expression in MCN of the PVN and SON [60] con-
sistent with the idea of inhibitory inputs on cAMP pro-
duction in osmotic stress. In addition, Rasd1 has been
seen to abolish dopamine D2L receptor mediated po-
tentiation of AC2 activity by blocking protein kinase C
and Gβγ activity [25], and to block dopamine D2L re-
ceptor mediated heterologous sensitization of AC1 [24].
Both AC1 and AC2 have been reported in the PVN and
SON [76], so could be targets of Rasd1 actions in these
brain nuclei as well as other brain regions that express
Rasd1.
To validate our in vitro findings in the physiological
context of the whole organisms, we used lentiviral vec-
tors to overexpress Rasd1 in the rat SON. Analogous to
our findings in AtT20 cells, overexpression of Rasd1 in
the SON reduced HS induced increases in c-Fos and
Nr4a1, and completely blocked induced hnAvp expres-
sion. Therefore, Rasd1 alone could mimic the actions of
DEX on these target genes in the SON, suggesting that
DEX effects in PVN and SON are mediated through al-
tered Rasd1 expression. We suggest that this is due to
inhibition of CREB phosphorylation. In a recent in vivo
study, injection of a recombinant adeno-associated virus
expressing ACREB, a dominant negative inhibitor of en-
dogenous CREB, into the SON resulted in decreased c-
Fos and Nr4a1 mRNA expression [77]. Furthermore in
the SCNs of Rasd1 knockout mice, Cheng et al. [26] re-
ported higher cAMP levels, alongside increased c-Fos
and CREB phosphorylation, compared to wild-type mice.
These changes in Rasd1 knockout mice are consistent
with removal of the inhibitory influences of Rasd1 on
cAMP dependent signaling pathways. This is consistent
with our findings with dnRasd1 overexpression in the
SON of the SL rat where expression levels of cAMP in-
ducible genes were increased. We would predict a simi-
lar mode of action for Rasd1 overexpression in PCNs of
the PVN based on our findings presented here. Unfortu-
nately, our viruses are not able to selectively discrimin-
ate between MCN and PCNs of the PVN to extend
these findings to PCNs of the PVN.
RASD1 has been shown to exist in ternary complex
with carboxy-terminal PDZ ligand CAPON and neur-
onal nitric oxide synthase (nNOS) [30]. This enables ac-
tivation of Rasd1 by s-nitrosylation on single cysteine
(Cys11) residue at the N-terminus of this protein [78].
In cortical neuronal cultures, Rasd1 is activated by nitric
oxide donors as well as N-methyl-D-aspartate receptor
stimulated nitric oxide synthesis [78]. The AVP express-
ing MCN of the SON express nNOS, RASD1, CAPON
[30] and nNos is also subjected to regulation by DH and
SL [79, 80]. We do not know whether RASD1 complexes
with nNOS and CAPON regulate any signaling events in
the SON, or indeed if s-nitrosylation of RASD1 is im-
portant. However, we do know that AtT20 cells do not
express nNos [81], so nNos is not a necessary component
for Rasd1 mediated inhibition of cAMP pathways.
Conclusion
In summary, our results showed that Rasd1 is expressed
in vasopressinergic neurons in the PVN and SON of the
hypothalamus. We identified two mechanisms of Rasd1
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induction in the hypothalamus, one by elevated gluco-
corticoids in response to stress, and one in response to
increased plasma osmolality resulting from osmotic
stress. The ability to influence c-Fos, Nr4a1, and hnAVP
in vivo by lentiviral gene transfer greatly strengthened
our hypothesis that Rasd1 was inhibiting cAMP-PKA-
CREB signaling pathway in the hypothalamus (Fig. 8).
We propose that the abundance of RASD1 in MCN,
based on these inhibitory actions, is important for con-
trolling the transcriptional response to osmotic stress in
the PVN and SON. In PCNs of the PVN, Rasd1 has all
the necessary credentials to facilitate the rapid gluco-
corticoid negative feedback of the HPA axis on Crh and
Avp expression. Studies have long proposed that an
intermediate signalling molecule activated by the GR
may be necessary for glucocorticoid negative feedback




Male Sprague–Dawley rats weighing 250–300 g were
used in this study, except for the restraint stress experi-
ment (performed in Brazil), where male Wistar rats
weighing 250–300 g were used. Rats were maintained
under a 14:10 light dark cycle (lights on at 0500) with
food and water ad libitum for at least 1 week prior to ex-
perimentation. Animal experiments were performed be-
tween 9 am–2 pm. All experiments in the UK were
performed under a Home Office UK licence held under,
and in strict accordance with, the provision of the UK
Animals (Scientific Procedures) Act (1986); they had also
been approved by the University of Bristol Animal Wel-
fare and Ethical Review Board. The experiments in Brazil
were conducted according to the “Guide for the Care
and Use of Laboratory Animals” (NIH Publication No.
85–23, revised 1996), and experimental protocols were
approved by the local Ethics Committee on Animal Use
in the School of Medicine of Ribeirão Preto, University
of São Paulo.
Hypertonic stress experiment
We used two protocols a chronic and an acute hyper-
tonic stress protocol. To induce chronic hyperosmotic
stress, water was removed (DH) for 1 or 3 days or re-
placed by 2% (w/v) NaCl in drinking water for 1 or
7 days SL. The control group had access to food and
water ad libitum. In some instances water was returned
after DH and SL for 24 h (rehydration). The acute re-
sponses were assessed (10 min, 30 min, 1, 2, or 4 h) after
a single i.p injection of 1.5 ml/100 g body weight of
1.5 M NaCl solution HS. After injection, HS rats were
placed back in their home cages and water was removed.
The reference group (time 0) had access to food and
water ad libitum. In acute experiments with time-point
comparisons the control groups received a single i.p in-
jection of IS solution (1.5 ml/100 g body weight of
0.15 M NaCl solution).
Restraint stress experiment
Rats were randomly allocated to 3 groups (control, 0.5 h
and 1 h restraint). The control group stayed in their
home cages and had access food and water ad libitum
throughout the experimental period. For RNA analysis,
animals were placed in clear plexiglass tubes with access
to air for either 0.5 h or 1 h duration, before being im-
mediately killed. For immunofluorescence protein ana-
lysis, the rats were killed 3 h after removal from the tube
to allow time for de novo protein synthesis to take place.
Glucocorticoid studies
To investigate actions of glucocorticoid on gene expres-
sion in the hypothalamus, rats were injected intraperito-
neally with 0.5 ml 0.15 M NaCl (vehicle) or 0.5 ml of
1 mg/kg body weight DEX (Sigma D2915) 2 h before IS
or HS injection. To inhibit the synthesis of endogenous
glucocorticoid, rats were injected subcutaneously with
0.5 ml sesame oil (vehicle), 150 mg/kg body weight MET
(Sigma 856525), which inhibits endogenous cortico-
sterone synthesis by inhibiting steroid 11-β hydroxylase
Fig. 8 Proposed mechanism of action of Rasd1 in cAMP-dependent
gene regulation. Rasd1 mRNA expression is upregulated by
glucocorticoid (dexamethasone) and increased plasma osmolality
(hypertonic stress). In the cytoplasm RASD1 undergoes posttranslational
processing by isoprenylation of its CAAX box motif enabling trafficking
to the cell membrane. RASD1 activates Gαi which inhibits the cAMP
dependent pathway by inhibiting adenylyl cyclase. This results in the
inhibition of the cAMP-PKA-CREB signalling pathway
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activity, or 150 mg/kg MET and 0.2 mg/kg body weight
DEX 4 h before IS or HS injection. After injection of HS
or IS rats were placed back in their home cages, and
water, but not food, was removed for the remaining
30 min of the experiment. For RNA analyses, rats were
killed by striking of the cranium, followed by decapita-
tion, using a guillotine (Harvard Apparatus). Brains were
removed and frozen on dry ice before being stored at
−80 °C.
RNA extraction and cDNA synthesis
Frozen brains were sliced into 60 μm coronal sections in
a cryostat. Sections were mounted on glass slides and
stained with 0.1% (w/v) toludine blue then visualised on
a light microscope until brain nuclei were visible, then
SON and PVN samples were collected using a 1 mm mi-
cro punch (Fine Scientific Tools). The optic chiasm
(SON), or neurons lateral to the third ventricle (PVN),
were used as a reference. SON and PVN samples were
then dispensed into 1.5 ml tubes and kept on dry ice
within the cryostat. Total RNA was extracted from
punched samples by combining Qiazol Reagent with
Qiagens RNeasy kit protocols (Qiagen). The punched
samples were removed from dry ice and rapidly resus-
pended, by vortexing, in 1 ml Qiazol reagent. Following
Qiazol phase separation with chloroform, 350 μl of the
upper aqueous phase was removed, mixed with 350 μl
70% (v/v) ethanol and applied to RNeasy columns. The
remaining steps were performed as recommended by the
manufacturer. For cDNA synthesis 200 ng (tissue) or
500 ng (cells) of total RNA was reverse transcribed using
the Quantitect reverse transcription kit (Qiagen).
Real-time quantitative PCR analysis
Primers for Rasd1 (Rat/Mouse, 5’-CCCTCAGCGTT
GTGCCTACT-3’ and 5’-AAAGAGCGCACGGAACAT
CT-3’), c-Fos (Rat, 5’-AGCATGGGCTCCCCTGTCA-3’
and 5'-GAGACCAGAGTGGGCTGCA-3'; Mouse, 5’-TC
CCCAAACTTCGACCATGA-3’ and 5’-GGCTGGGGA
ATGGTAGTAGG-3’), Nr4a1 (Rat, 5'-CTGCGACTGG
GTCCTGGGTC-3' and 5'-TGTCAGGTGGTCACGCG
GTC-3'; Mouse, 5’-AAAGTTGGGGGAGTGTGCTA-3’
and 5’-GAATACAGGGCATCTCCAGC-3’), rat hnCrh
(5'-GGGCGAATAGCTTAAACCTG-3' and 5'-CAGGT
GACCCTTCCTTGGAGA-3'), mouse GR (5’-TGTCAC
TGCTGGAGGTGATT-3’ and 5'-ATCACTTGACGCC
CACCTAA-3'), rat hnAvp (5'-GAGGCAAGAGGGCCA
CATC-3' and 5'-CTCTCCTAGCCCATGACCCTT-3'),
rat mature Avp (5'-TGCCTGCTACTTCCAGAACTGC-




GGCGATTTCGTTG-3') and Gapdh (Rat, 5’-ATGATT
CTACCCACGGCAAG-3’ and 5’-CTGGAAGATGGT
GATGGGTT-3’; Mouse, 5’-CAACTCCCACTCTTCCA
CCT-3’ and 5’-CTTGCTCAGTGTCCTTGCTG-3’) were
synthesised by Eurofins MWG Operon. The qPCRs were
carried out in duplicate using SYBR green (Roche) on an
ABI StepOnePlus Sequence Detection System (ABI,
Warrington, UK). For relative quantification of gene ex-
pression the 2-ΔΔCT method was employed [82]. The in-
ternal control gene used for these analyses were the
housekeeping gene Rpl19 and Gapdh. To analyse Rasd1
and GR gene knockdown PCRs for gel electrophoresis
were performed using TaqDNA polymerase (New
England Biolabs).
Immunofluorescence
Rats were deeply anesthetised with sodium pentobarbit-
one (100 mg/kg i.p.) and transcardially perfused with
0.1 M phosphate buffered saline (PBS, pH 7.4) followed
by 4% (w/v) paraformaldehyde (PFA) in PBS. Brains were
removed and post-fixed overnight in 4% (w/v) PFA
followed by 30% (w/v) sucrose prepared in PBS. Tissues
were sectioned to 40 μm on a cryostat, washed in PBS
and blocked for 30 min in 5% (v/v) horse serum in PBS
containing 0.25% (v/v) Triton X-100 (PBST). Sections
were incubated with 1:500 dilution of rabbit anti-RASD1
antibody (Abcam, ab78459), 1:100 mouse anti-OT (neu-
rophysin-I, PS38, [83]) or 1:100 mouse anti-AVP (neuro-
physin-II, PS41) prepared in 1% (v/v) horse serum in
PBST at 4 °C overnight. The Rasd1 antibody has previ-
ously been shown to detect Rasd1 in mouse brain ex-
tracts by Western blot (data sheet), mouse kidney by
immunohistochemistry (data sheet), and rat pancreas by
immunofluorescence [47]. The sections were washed
three times in PBS for 5 min and incubated with 1:500
dilution of anti-rabbit IgG-biotinylated secondary anti-
body in PBST for 1 h at room temperature. Sections
were washed three times for 5 min with PBS and incu-
bated for 1 h with secondary antibodies conjugated with
fluorophore Alexa Fluor 488 streptavidin-conjugated and
Alexa Fluor 594 donkey anti-mouse (Invitrogen). Sec-
tions were mounted and sealed with VectorShields
mounting media (Vector Laboratories).
The GFP-Rasd1 fusion construct was generated by
overlap extension PCR. Primers for GFP (5’-CGCGG
ATCCATGGTGAGCAAGGGCGAGGA-3’ and 5’-CTT
GTACAGCTCGTCCATGCCGA-3’) and Rasd1 (5’-TCG
GCATGGACGAGCTGTACAAGAAACTGGCCGCGAT
GAA-3’ and 5’-ACGCGTCGACCTAACTGATGACACA
GCGCT-3’) were used for PCRs using Phusion High-
FidelityDNAPolymerase (New England BioLabs). The final
PCR product was digested with BamH1 and SalI and
cloned into the corresponding sites of pcDNA3.1. N2a
cells were grown on coverslips in 12-well tissue culture
plates and transfected with GFP-Rasd1 fusion construct
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using Lipofectamine LTX (Life Technologies). At 48 h
after transfections cells were fixed with 4% (w/v) PFA in
PBS for 10 min and washed three times with PBS for
5 min. Cells were then incubated with 0.3% (v/v) Triton
X-100 in PBS for 10 min for permeabilisation followed by
5% (v/v) horse serum prepared in PBS with 0.03% (v/v)
Triton X-100 for 30 min for blocking. Cells were incu-
bated with 1:500 dilution of rabbit anti-RASD1 antibody
(Abcam, ab78459) prepared in 1% (v/v) horse serum in
PBS-0.03 T at 4 °C overnight. After three washes, cells
were incubated with Alexa Fluor 594 donkey anti-rabbit
IgG (1:500; Invitrogen) for 1 h at room temperature,
followed by three washes with PBS-0.03 T. Coverslips
were mounted onto glass slides using VectorShields hard
mounting media with DAPI. Images were captured on a
confocal microscope (Leica).
Protein extraction and immunoblotting
Cells were washed twice with cold PBS pH 7.4 (Gibco;
10010–015), and harvested by scraping into RIPA buffer,
consisting of PBS containing 1% (v/v) IGEPAL CA-630
(Sigma I3021), 0.5% (w/v) sodium deoxycholate, and
0.1% (w/v) sodium dodecyl sulfate, 1 mM PMSF, prote-
ase inhibitor (Sigma: P8340) and phosphatase inhibitor
(Roche: 04906845001). The lysate was incubated on ice
for 15 min with vortexing every 5 min, followed by cen-
trifugation at 10,000 × g for 10 min. Supernatants were
collected and kept at −80 °C. Protein concentrations
were determined using the Bradford assay (Bio-Rad).
For immunoblotting, proteins (50 μg) were separated
by SDS-PAGE and transferred to 0.45 μm PVDF mem-
branes (Millipore). The membranes were blocked with
3% (w/v) ECL Prime blocking agent (GE Healthcare) in
Tris-buffered saline-Tween 20 (0.1% (v/v) TBS-T) for
1 h at room temperature, followed by incubation with
primary antibody diluted in 3% (w/v) ECL Prime block-
ing agent in TBST at 4 °C overnight. This was followed
by incubation with appropriate secondary antibody con-
jugated with horseradish peroxidase (HRP) at room
temperature for 1 h. Membranes were washed with
TBST. Signal was visualized using high sensitivity WES-
TAR EtaC or WESTAR SuperNova extreme sensitivity
HRP Detection Substrate (Cyanagen). Primary antibodies
used: a rabbit polyclonal anti-RASD1 (1:1000; Abcam,
ab78459), goat polyclonal anti-phosphoCREB (1:2500;
Santa Cruz, sc-7978), and a mouse polyclonal anti-
GAPDH (1:20,000; Santa Cruz, sc-32233) antibody. Im-
munoblots were stripped in Restore Western blot strip-
ping buffer (ThermoScientific) and re-probed to assess
multiple proteins in the same blot.
Organotypic studies
Organotypic cultures were prepared as described
previously [84]. Sprague–Dawley pups (P5–P7) were
purchased from Harlan Laboratories (UK). Pups were
decapitated using scissors, and brains were removed and
incubated in cold-Hank’s solution for 5 min, and then
dissected using the optic chiasm as a landmark to pro-
duce a hypothalamic block. Slices (400 μm) were cut on
a Mcllwain Tissue Chopper and placed onto hydrated
Millipore Millicell-CM filter inserts in 6 well tissue cul-
ture plates containing 1.1 ml of culture medium. After
10 day, culture medium was replaced with serum free
medium. The cultures were incubated at 35 °C in 5% (v/
v) CO2 enriched air and medium was replaced every
2 days. Experimental treatments were performed after
4 days in serum free medium. Slice cultures were incu-
bated with 0.01% (v/v) DMSO (vehicle) or 100nM DEX
prepared in serum free medium for 4 h or 24 h. The in-
serts were frozen on dry ice in 6-well tissue culture
plates, SON and PVN were punched (1 mm diameter
micropunch) from 3 slices in a cryostat and RNA was
extracted as described above.
Cells and treatments
Mouse pituitary cell line AtT20/D16v-F2 (Sigma;
94050406), Human Embryonic Kidney cells HEK293T/
17 (ATTC CRL-11268), and Mouse Neuroblastoma N2a
cells (ATTC CCL-131) were cultured in DMEM (Sigma;
D6546) supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (Gibco), 2 mM L-glutamine and 100
unit/ml of penicillin-streptomycin. Cells were incubated
at 37 °C in a humidified incubator with 5% (v/v) CO2.
For chemical treatments, cells were seeded onto tissue
culture plates to 60–70% confluence. After 24–72 h
chemical treatments were performed at the time points
indicated in the figure legend; 10 μM FSK (Sigma:
F6886) and/or 100nM DEX (Sigma: D1756), or 10 μM
FTI-277 (Sigma). Stock solutions of FSK (10 mM) and
DEX (100 μM) were prepared in DMSO while FTI-277
(2.5 mM) was prepared in water.
To produce knockdown cell lines, AtT20 cells were
transduced with a lentivirus containing shRNAs target-
ing mouse Rasd1 or GR. The shRNA sequences (Rasd1
shRNA1-GCCGTTTCGAGGATGCTTCAA, shRNA2-
GCTCAAACAGCAGATCCTAGA; GR- GGAGATAC
AATCTTATCAAGC) were obtained from the RNAi
consortium shRNA library. Sense and antisense oligonu-
cleotides for shRNAs were synthesised (European MWG
Operon) and cloned into lentiviral transfer vector
pLKO.1 puro according to manufacturer’s guidelines
(pLKO.1 puro was a gift from Bob Weinberg, Addgene
plasmid 8453) [85]. A non-targeting shRNA sequence
(ATCATGTTAGGCGTACGGACT) was used as a con-
trol. Virus particles were produced as previously de-
scribed [86]. Twenty four hours after transduction,
culture media was replaced with fresh media containing
puromycin (2 μg/ml, Life Technologies). The cells were
Greenwood et al. Molecular Brain  (2016) 9:1 Page 14 of 17
cultured in presence of puromycin for two weeks before
use in experiments. The level of knockdown was con-
firmed by qPCR.
Adenoviral vector synthesis
cDNA clones encoding mouse Rasd1 and a dnRasd1
were the kind gift of Professor Richard Dorin, University
of New Mexico. cDNAs were excised from pcDNA3.1
with restriction enzymes KpnI and XhoI and ligated
into compatible restriction sites of adenoviral vector
pacAd5.CMV (Cell Biolabs). Adenoviral vector pac
Ad5.CMV.eGFP was used as a control. The adenoviruses
were generated by co-transfection of viral shuttle and
backbone (pacAd5 9.2-100) vectors in HEK293T cells by
calcium phosphate method in accordance with manufac-
turer’s guidelines (Cell Biolabs). Adenoviruses were puri-
fied by two rounds of CsCl ultracentrifugation and
desalted using Slide-A-Lyzer dialysis cassettes (Thermo-
scientific). The purified viruses were aliquoted and stored
at −80 °C. The virus titers were determined in triplicate by
standard plaque assay. A multiplicity of infection of 10
was used for cell experiments.
Lentiviral vector gene transfer into SON
We used lentiviral vectors to study Rasd1 overexpression
in the rat brain due to their higher infectivity of neurons
compared to adenoviruses [87]. The cDNA clones of
Rasd1 and dnRasd1 were excised from plasmid
pcDNA3.1 and expressed in lentiviral vector
pRRL.SIN.CPPT.CMV.IRES.eGFP.WPRE (modified from
Addgene plasmid 12252). A lentiviral vector expressing
eGFP (pRRL.SIN.CPPT.CMV.eGFP.WPRE) was used as
a control. Viruses were generated as described previ-
ously [86]. Titers were calculated in transduction units
per ml (TU/ml) with all viruses in the present study hav-
ing a titer of > 5 x 109 TU/ml.
Stereotaxic injections of lentiviral vectors into the
SON were performed as previously described [84]. Lenti-
viral vector tropism was assessed by visualising GFP
expression in perfused tissue. To investigate gene ex-
pression following overexpression of Rasd1 or dnRasd1
in the SON, rats received bilateral lentiviral injections,
where Rasd1 or dnRasd1 virus was administered to one
nuclei and eGFP into the other and viral expression was
allowed to proceed for two weeks. Two weeks after
Rasd1 virus administration rats received a single i.p in-
jection of either IS (0.15 M NaCl) or HS (1.5 M NaCl;
1.5 ml/100 g body weight) and were killed 30 min later.
Two weeks after dnRasd1 virus administration rats were
SL for 7 days.
Statistical analysis
Statistical differences between two experimental groups
were evaluated using independent-sample unpaired
Student’s t tests. One-way ANOVA with Tukey’s post
hoc test were used to determine the difference between
more than two samples with only a single influencing
factor. Two-way ANOVA with Bonferonni post hoc test
was used to determine interactions between two inde-
pendent variables on the dependent variable. p < 0.05
was considered significant.
Competing interests
The authors declare no competing financial or non-financial interests.
Authors’ contributions
MPG established knockdown cell lines, carried out animal studies,
participated in organotypic culture, performed the statistical analysis and
drafted the manuscript. MG carried out cell culture, organotypic culture and
molecular studies, participated in the design of the study and helped to
draft the manuscript. ASM participated in animal experiment and
participated in design of the study. JAR, JFRP and DM conceived of the
study, participated in its design and coordination and helped to draft the
manuscript.
Acknowledgements
We would like to thank Prof. Harold Gainer (NINDS, NIH, USA) for providing
us with antibodies recognising AVP neurophysin-II and OT neurophysin-I. We
gratefully acknowledge the support of the MRC (G0700954, DM), BBSRC (BB/
G006156/1, MPG, JP, DM; BB/J015415/1, MG, JP, DM), University of Malaya
(HIR award H-20001-E0000865, ASM, DM), and Sao Paulo Research
Foundation FAPESP (2011/52108-4, JAR; 2013/09799-1, JAR).
Author details
1School of Clinical Sciences, University of Bristol, Bristol BS1 3NY, UK. 2School
of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
3Department of Physiology, University of Malaya, Kuala Lumpur 50603,
Malaysia. 4Department of Physiological Sciences, Biology Institute, Federal
Rural University of Rio de Janeiro, Seropedica, Rio de Janeiro, Brazil. 5School
of Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
Received: 10 November 2015 Accepted: 23 December 2015
References
1. Antunes-Rodrigues J, de Castro M, Elias LL, Valenca MM, McCann SM.
Neuroendocrine control of body fluid metabolism. Physiol Rev.
2004;84(1):169–208.
2. Papadimitriou A, Priftis KN. Regulation of the hypothalamic-pituitary-adrenal
axis. Neuroimmunomodulation. 2009;16(5):265–71.
3. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine
corticotropin-releasing factor immunoreactive cells and fibers in the
rat brain: an immunohistochemical study. Neuroendocrinology.
1983;36(3):165–86.
4. Vandesande F, Dierickx K, De Mey J. The origin of the vasopressinergic and
oxytocinergic fibres of the external region of the median eminence of the
rat hypophysis. Cell Tissue Res. 1977;180(4):443–52.
5. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin
secretion comes of age. Front Neuroendocrinol. 1993;14(2):76–122.
6. DeBold CR, DeCherney GS, Jackson RV, Sheldon WR, Alexander AN, Island
DP, et al. Effect of synthetic ovine corticotropin-releasing factor: prolonged
duration of action and biphasic response of plasma adrenocorticotropin
and cortisol. J Clin Endocrinol Metab. 1983;57(2):294–8.
7. Kovacs KJ, Foldes A, Sawchenko PE. Glucocorticoid negative feedback
selectively targets vasopressin transcription in parvocellular neurosecretory
neurons. J Neurosci. 2000;20(10):3843–52.
8. Kovacs KJ, Sawchenko PE. Regulation of stress-induced transcriptional
changes in the hypothalamic neurosecretory neurons. J Mol Neurosci.
1996;7(2):125–33.
9. Kovacs KJ, Sawchenko PE. Sequence of stress-induced alterations in indices
of synaptic and transcriptional activation in parvocellular neurosecretory
neurons. J Neurosci. 1996;16(1):262–73.
Greenwood et al. Molecular Brain  (2016) 9:1 Page 15 of 17
10. Murphy D, Carter D. Vasopressin gene expression in the rodent
hypothalamus: transcriptional and posttranscriptional responses to
physiological stimulation. Molecular endocrinology (Baltimore. Md.
1990;4(7):1051–9.
11. Yoshida M. Gene regulation system of vasopressin and corticotropin-
releasing hormone. Gene regulation and systems biology. 2008;2:71–88.
12. Legradi G, Holzer D, Kapcala LP, Lechan RM. Glucocorticoids inhibit stress-
induced phosphorylation of CREB in corticotropin-releasing hormone
neurons of the hypothalamic paraventricular nucleus. Neuroendocrinology.
1997;66(2):86–97.
13. Shiromani PJ, Magner M, Winston S, Charness ME. Time course of
phosphorylated CREB and Fos-like immunoreactivity in the hypothalamic
supraoptic nucleus after salt loading. Brain Res. 1995;29(1):163–71.
14. Ceccatelli S, Cintra A, Hokfelt T, Fuxe K, Wikstrom AC, Gustafsson JA.
Coexistence of glucocorticoid receptor-like immunoreactivity with
neuropeptides in the hypothalamic paraventricular nucleus. Exp Brain Res.
1989;78(1):33–42.
15. Kiss JZ, Van Eekelen JA, Reul JM, Westphal HM, De Kloet ER. Glucocorticoid
receptor in magnocellular neurosecretory cells. Endocrinology. 1988;122(2):444–9.
16. Berghorn KA, Knapp LT, Hoffman GE, Sherman TG. Induction of
glucocorticoid receptor expression in hypothalamic magnocellular
vasopressin neurons during chronic hypoosmolality. Endocrinology.
1995;136(2):804–7.
17. Han F, Ozawa H, Matsuda K, Nishi M, Kawata M. Colocalization of
mineralocorticoid receptor and glucocorticoid receptor in the hippocampus
and hypothalamus. Neurosci Res. 2005;51(4):371–81.
18. Kemppainen RJ, Behrend EN. Dexamethasone rapidly induces a novel
ras superfamily member-related gene in AtT-20 cells. J Biol Chem.
1998;273(6):3129–31.
19. Kemppainen RJ, Cox E, Behrend EN, Brogan MD, Ammons JM. Identification
of a glucocorticoid response element in the 3'-flanking region of the
human Dexras1 gene. Biochim Biophys Acta. 2003;1627(2–3):85–9.
20. Brogan MD, Behrend EN, Kemppainen RJ. Regulation of Dexras1 expression
by endogenous steroids. Neuroendocrinology. 2001;74(4):244–50.
21. Graham TE, Key TA, Kilpatrick K, Dorin RI. Dexras1/AGS-1, a steroid hormone-
induced guanosine triphosphate-binding protein, inhibits 3',5'-cyclic
adenosine monophosphate-stimulated secretion in AtT-20 corticotroph
cells. Endocrinology. 2001;142(6):2631–40.
22. Graham TE, Qiao Z, Dorin RI. Dexras1 inhibits adenylyl cyclase. Biochem
Biophys Res Commun. 2004;316(2):307–12.
23. Harrison LM, He Y. Rhes and AGS1/Dexras1 affect signaling by dopamine D1
receptors through adenylyl cyclase. J Neurosci Res. 2011;89(6):874–82.
24. Nguyen CH, Watts VJ. Dexras1 blocks receptor-mediated heterologous
sensitization of adenylyl cyclase 1. Biochem Biophys Res Commun.
2005;332(3):913–20.
25. Nguyen CH, Watts VJ. Dexamethasone-induced Ras protein 1 negatively
regulates protein kinase C delta: implications for adenylyl cyclase 2
signaling. Mol Pharmacol. 2006;69(5):1763–71.
26. Cheng HY, Dziema H, Papp J, Mathur DP, Koletar M, Ralph MR, et al. The
molecular gatekeeper Dexras1 sculpts the photic responsiveness of the
mammalian circadian clock. J Neurosci. 2006;26(50):12984–95.
27. Ong SA, Tan JJ, Tew WL, Chen KS. Rasd1 modulates the coactivator function
of NonO in the cyclic AMP pathway. PLoS One. 2011;6(9):e24401.
28. Hindmarch C, Yao S, Beighton G, Paton J, Murphy D. A comprehensive
description of the transcriptome of the hypothalamoneurohypophyseal
system in euhydrated and dehydrated rats. Proc Natl Acad Sci U S A.
2006;103(5):1609–14.
29. Stewart L, Hindmarch CC, Qiu J, Tung YC, Yeo GS, Murphy D. Hypothalamic
transcriptome plasticity in two rodent species reveals divergent differential gene
expression but conserved pathways. J Neuroendocrinol. 2011;23(2):177–85.
30. Fang M, Jaffrey SR, Sawa A, Ye K, Luo X, Snyder SH. Dexras1: a G protein
specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron.
2000;28(1):183–93.
31. Takahashi H, Umeda N, Tsutsumi Y, Fukumura R, Ohkaze H, Sujino M, et al.
Mouse dexamethasone-induced RAS protein 1 gene is expressed in a
circadian rhythmic manner in the suprachiasmatic nucleus. Brain Res.
2003;110(1):1–6.
32. Cheng HY, Obrietan K. Dexras1: shaping the responsiveness of the circadian
clock. Semin Cell Dev Biol. 2006;17(3):345–51.
33. Mezey E, Kiss JZ. Coexpression of vasopressin and oxytocin in hypothalamic
supraoptic neurons of lactating rats. Endocrinology. 1991;129(4):1814–20.
34. Ma XM, Levy A, Lightman SL. Rapid changes in heteronuclear RNA for
corticotrophin-releasing hormone and arginine vasopressin in response to
acute stress. J Endocrinol. 1997;152(1):81–9.
35. Ponzio TA, Yue C, Gainer H. An intron-based real-time PCR method for
measuring vasopressin gene transcription. J Neurosci Methods.
2007;164(1):149–54.
36. de Quervain DJ, Roozendaal B, McGaugh JL. Stress and glucocorticoids
impair retrieval of long-term spatial memory. Nature. 1998;394(6695):787–90.
37. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, et al. Ras CAAX
peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by
inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol
Chem. 1995;270(45):26802–6.
38. Aguilera G, Lightman SL, Kiss A. Regulation of the hypothalamic-pituitary-
adrenal axis during water deprivation. Endocrinology. 1993;132(1):241–8.
39. Dohanics J, Kovacs KJ, Folly G, Makara GB. Long-term salt loading impairs
pituitary responsiveness to ACTH secretagogues and stress in rats. Peptides.
1990;11(1):59–63.
40. Dohanics J, Verbalis JG. Naloxone disinhibits magnocellular responses to
osmotic and volemic stimuli in chronically hypoosmolar rats.
J Neuroendocrinol. 1995;7(1):57–62.
41. Kiss A, Aguilera G. Regulation of the hypothalamic pituitary adrenal axis
during chronic stress: responses to repeated intraperitoneal hypertonic
saline injection. Brain Res. 1993;630(1–2):262–70.
42. Dallman MF, Akana SF, Scribner KA, Bradbury MJ, Walker CD, Strack AM,
et al. Stress, feedback and facilitation in the hypothalamo-pituitary-adrenal
axis. J Neuroendocrinol. 1992;4(5):517–26.
43. Pitman DL, Ottenweller JE, Natelson BH. Plasma corticosterone levels during
repeated presentation of two intensities of restraint stress: chronic stress
and habituation. Physiol Behav. 1988;43(1):47–55.
44. Cha JY, Kim HJ, Yu JH, Xu J, Kim D, Paul BD, et al. Dexras1 mediates
glucocorticoid-associated adipogenesis and diet-induced obesity. Proc Natl
Acad Sci U S A. 2013;110(51):20575–80.
45. Kushner SA, Elgersma Y, Murphy GG, Jaarsma D, van Woerden GM, Hojjati
MR, et al. Modulation of presynaptic plasticity and learning by the H-ras/
extracellular signal-regulated kinase/synapsin I signaling pathway.
J Neurosci. 2005;25(42):9721–34.
46. Compton SL, Kemppainen RJ, Behrend EN. Prenylated Rab acceptor domain
family member 1 is involved in stimulated ACTH secretion and inhibition.
Cell Signal. 2009;21(12):1901–9.
47. Lellis-Santos C, Sakamoto LH, Bromati CR, Nogueira TC, Leite AR, Yamanaka
TS, et al. The regulation of Rasd1 expression by glucocorticoids and
prolactin controls peripartum maternal insulin secretion. Endocrinology.
2012;153(8):3668–78.
48. McGrath MF, Ogawa T, de Bold AJ. Ras dexamethasone-induced protein 1 is
a modulator of hormone secretion in the volume overloaded heart. Am J
Physiol Heart Circ Physiol. 2012;302(9):H1826–37.
49. Meister B, Cortes R, Villar MJ, Schalling M, Hokfelt T. Peptides and
transmitter enzymes in hypothalamic magnocellular neurons after
administration of hyperosmotic stimuli: comparison between messenger
RNA and peptide/protein levels. Cell Tissue Res. 1990;260(2):279–97.
50. Reaux-Le Goazigo A, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A.
Dehydration-induced cross-regulation of apelin and vasopressin
immunoreactivity levels in magnocellular hypothalamic neurons.
Endocrinology. 2004;145(9):4392–400.
51. Cismowski MJ, Ma C, Ribas C, Xie X, Spruyt M, Lizano JS, et al. Activation of
heterotrimeric G-protein signaling by a ras-related protein. Implications for
signal integration. J Biol Chem. 2000;275(31):23421–4.
52. Graham TE, Prossnitz ER, Dorin RI. Dexras1/AGS-1 inhibits signal
transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP
kinases. J Biol Chem. 2002;277(13):10876–82.
53. Imaki T, Xiao-Quan W, Shibasaki T, Yamada K, Harada S, Chikada N, et al.
Stress-induced activation of neuronal activity and corticotropin-releasing
factor gene expression in the paraventricular nucleus is modulated by
glucocorticoids in rats. J Clin Invest. 1995;96(1):231–8.
54. Kovacs KJ, Mezey E. Dexamethasone inhibits corticotropin-releasing factor
gene expression in the rat paraventricular nucleus. Neuroendocrinology.
1987;46(4):365–8.
55. Lauand F, Ruginsk SG, Rodrigues HL, Reis WL, de Castro M, Elias LL, et al.
Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin
and Fos expression in response to osmotic, angiotensinergic and
cholinergic stimulation. Neuroscience. 2007;147(1):247–57.
Greenwood et al. Molecular Brain  (2016) 9:1 Page 16 of 17
56. Kiss JZ, Mezey E, Skirboll L. Corticotropin-releasing factor-immunoreactive
neurons of the paraventricular nucleus become vasopressin positive after
adrenalectomy. Proc Natl Acad Sci U S A. 1984;81(6):1854–8.
57. Suemaru S, Hashimoto K, Ogasa T, Takao T, Ota Z, Hirakawa M, et al. Effects
of hyperosmotic stimulation and adrenalectomy on vasopressin mRNA
levels in the paraventricular and supraoptic nuclei of the hypothalamus: in
situ hybridization histochemical analysis using a synthetic oligonucleotide
probe. Acta Med Okayama. 1990;44(5):233–41.
58. Carter DA, Murphy D. Cyclic nucleotide dynamics in the rat hypothalamus
during osmotic stimulation: in vivo and in vitro studies. Brain Res.
1989;487(2):350–6.
59. Ceding P, Schilling K, Schmale H. Vasopressin Expression in Cultured
Neurons is Stimulated by Cyclic AMP. J Neuroendocrinol. 1990;2(6):859–65.
60. Young 3rd WS, Shepard EA, Burch RM. Plasma hyperosmolality increases G
protein and 3',5'-cyclic adenosine monophosphate synthesis in the
paraventricular and supraoptic nuclei. Molecular endocrinology (Baltimore,
Md). 1987;1(12):884–8.
61. Fass DM, Butler JE, Goodman RH. Deacetylase activity is required for cAMP
activation of a subset of CREB target genes. J Biol Chem. 2003;278(44):43014–9.
62. Chan RK, Brown ER, Ericsson A, Kovacs KJ, Sawchenko PE. A comparison
of two immediate-early genes, c-fos and NGFI-B, as markers for
functional activation in stress-related neuroendocrine circuitry. J
Neurosci. 1993;13(12):5126–38.
63. Kawasaki M, Yamaguchi K, Saito J, Ozaki Y, Mera T, Hashimoto H, et al.
Expression of immediate early genes and vasopressin heteronuclear RNA in
the paraventricular and supraoptic nuclei of rats after acute osmotic
stimulus. J Neuroendocrinol. 2005;17(4):227–37.
64. Martin LJ, Tremblay JJ. Glucocorticoids antagonize cAMP-induced Star
transcription in Leydig cells through the orphan nuclear receptor NR4A1.
J Mol Endocrinol. 2008;41(3):165–75.
65. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid
addition to Ras protein is the critical modification for its membrane
association and transforming activity. Proc Natl Acad Sci U S A.
1992;89(14):6403–7.
66. Clarke S. Protein isoprenylation and methylation at carboxyl-terminal
cysteine residues. Annu Rev Biochem. 1992;61:355–86.
67. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications.
Farnesyl transferase inhibitors. J Lipid Res. 2006;47(1):15–31.
68. Khan OM, Ibrahim MX, Jonsson IM, Karlsson C, Liu M, Sjogren AK, et al.
Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates
macrophages and induces erosive arthritis in mice. J Clin Invest.
2011;121(2):628–39.
69. Stamatakis K, Cernuda-Morollon E, Hernandez-Perera O, Perez-Sala D.
Isoprenylation of RhoB is necessary for its degradation. A novel determinant
in the complex regulation of RhoB expression by the mevalonate pathway.
J Biol Chem. 2002;277(51):49389–96.
70. Hazell GG, Hindmarch CC, Pope GR, Roper JA, Lightman SL, Murphy D, et al.
G protein-coupled receptors in the hypothalamic paraventricular and
supraoptic nuclei–serpentine gateways to neuroendocrine homeostasis.
Front Neuroendocrinol. 2012;33(1):45–66.
71. Blumer JB, Cismowski MJ, Sato M, Lanier SM. AGS proteins: receptor-
independent activators of G-protein signaling. Trends Pharmacol Sci.
2005;26(9):470–6.
72. Wie J, Kim J, Ha K, Zhang YH, Jeon JH, So I. Dexamethasone activates
transient receptor potential canonical 4 (TRPC4) channels via Rasd1 small
GTPase pathway. Pflugers Arch. 2015;467(10):2081–91.
73. Nedungadi TP, Cunningham JT. Differential regulation of TRPC4 in the
vasopressin magnocellular system by water deprivation and hepatic
cirrhosis in the rat. American journal of physiology. 2014;306(5):R304–14.
74. Obukhov AG, Nowycky MC. TRPC4 can be activated by G-protein-coupled
receptors and provides sufficient Ca(2+) to trigger exocytosis in
neuroendocrine cells. J Biol Chem. 2002;277(18):16172–8.
75. Thapliyal A, Bannister RA, Hanks C, Adams BA. The monomeric G proteins
AGS1 and Rhes selectively influence Galphai-dependent signaling to
modulate N-type (CaV2.2) calcium channels. Am J Physiol Cell Physiol.
2008;295(5):C1417–26.
76. Mons N, Cooper DM. Adenylyl cyclase mRNA expression does not reflect
the predominant Ca2+/calmodulin-stimulated activity in the hypothalamus.
J Neuroendocrinol. 1994;6(6):665–71.
77. Lubelski D, Ponzio TA, Gainer H. Effects of A-CREB, a dominant negative
inhibitor of CREB, on the expression of c-fos and other immediate early
genes in the rat SON during hyperosmotic stimulation in vivo. Brain Res.
2012;1429:18–28.
78. Jaffrey SR, Fang M, Snyder SH. Nitrosopeptide mapping: a novel
methodology reveals s-nitrosylation of dexras1 on a single cysteine residue.
Chem Biol. 2002;9(12):1329–35.
79. Kadowaki K, Kishimoto J, Leng G, Emson PC. Up-regulation of nitric oxide
synthase (NOS) gene expression together with NOS activity in the rat
hypothalamo-hypophysial system after chronic salt loading: evidence of a
neuromodulatory role of nitric oxide in arginine vasopressin and oxytocin
secretion. Endocrinology. 1994;134(3):1011–7.
80. Ueta Y, Levy A, Chowdrey HS, Lightman SL. Water deprivation in the rat
induces nitric oxide synthase (NOS) gene expression in the hypothalamic
paraventricular and supraoptic nuclei. Neurosci Res. 1995;23(3):317–9.
81. Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, Rickman C, et al.
Specific targeting of pro-death NMDA receptor signals with differing
reliance on the NR2B PDZ ligand. J Neurosci. 2008;28(42):10696–710.
82. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
(San Diego, Calif). 2001;25(4):402–8.
83. Ben-Barak Y, Russell JT, Whitnall MH, Ozato K, Gainer H. Neurophysin in the
hypothalamo-neurohypophysial system. I. Production and characterization
of monoclonal antibodies. J Neurosci. 1985;5(1):81–97.
84. Greenwood MP, Greenwood M, Paton JF, Murphy D. Control of Polyamine
Biosynthesis by Antizyme Inhibitor 1 Is Important for Transcriptional
Regulation of Arginine Vasopressin in the Male Rat Hypothalamus.
Endocrinology. 2015;156(8):2905–17.
85. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al.
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA
(New York, NY). 2003;9(4):493–501.
86. Greenwood M, Bordieri L, Greenwood MP, Rosso Melo M, Colombari DS,
Colombari E, et al. Transcription factor CREB3L1 regulates vasopressin gene
expression in the rat hypothalamus. J Neurosci. 2014;34(11):3810–20.
87. Duale H, Kasparov S, Paton JF, Teschemacher AG. Differences in
transductional tropism of adenoviral and lentiviral vectors in the rat
brainstem. Exp Physiol. 2005;90(1):71–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Greenwood et al. Molecular Brain  (2016) 9:1 Page 17 of 17
